Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models-Reference-Cited by-同舟云学术

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models

Published:2018-04-13 Issue:1 Volume:3 Page:
ISSN:2059-3635
Container-title:Signal Transduction and Targeted Therapy
language:en
Short-container-title:Sig Transduct Target Ther

Author:

Syn Nicholas L.,Lim Pei Li,Kong Li Ren,Wang Lingzhi,Wong Andrea Li-Ann,Lim Chwee Ming,Loh Thomas Kwok Seng,Siemeister Gerhard,Goh Boon Cher,Hsieh Wen-Son

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics

Link

http://www.nature.com/articles/s41392-018-0010-0.pdf

Reference38 articles.

1. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).

2. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009).

3. Johnson, N. & Shapiro, G. I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin. Ther. Targets 14, 1199–1212 (2010).

4. Weinert, T. A. DNA damage checkpoint meets the cell cycle engine. Science 277, 1450–1451 (1997).

5. Shapiro, G. I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10, 4270s–4275s (2004).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of the link between COVID-19 and gastric cancer from the perspective of bioinformatics and systems biology;2024-04-04

2. Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets;Cancers;2024-02-23

3. An Overview of CDK Enzyme Inhibitors in Cancer Therapy;Current Cancer Drug Targets;2023-09

4. Synthesis, X-ray crystal structure, DFT calculation and anti-tumor research of novel-configurational dihydroartemisinin purine hybrids;Molecular Crystals and Liquid Crystals;2022-08-19

5. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors;Journal of Hematology & Oncology;2022-07-07